135 related articles for article (PubMed ID: 7226163)
1. Ethinyl estradiol and medroxyprogesterone treatment in advanced breast cancer: a pilot study.
Pellegrini A; Massidda B; Mascia V; Ionta MT; Lippi MG; Muggiano A; Carboni E; Robustelli della Cuna G; Bernardo G; Strada MR; Pavesi L
Cancer Treat Rep; 1981; 65(1-2):135-6. PubMed ID: 7226163
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer.
Nagel GA; Wander HE; Blossey HC
Cancer Res; 1982 Aug; 42(8 Suppl):3442s-3444s. PubMed ID: 6123383
[TBL] [Abstract][Full Text] [Related]
3. Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study.
Freedman RS; Saul PB; Edwards CL; Jolles CJ; Gershenson DM; Jones LA; Atkinson EN; Dana WJ
Cancer Treat Rep; 1986 Mar; 70(3):369-73. PubMed ID: 2937533
[TBL] [Abstract][Full Text] [Related]
4. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
5. [Additive treatment of metastasizing breast cancer with special reference to postmenopausal age (results of a randomized study)].
Firusian N; Schietzel M
Strahlentherapie; 1976 Sep; 152(3):235-47. PubMed ID: 968923
[TBL] [Abstract][Full Text] [Related]
6. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary curative treatment for disseminated carcinoma of the breast.
Mannes P; Derriks R; Moens R; Laurent C; Dalcq JM
Cancer Treat Rep; 1976 Jan; 60(1):85-9. PubMed ID: 1000521
[TBL] [Abstract][Full Text] [Related]
8. [Sequential therapy with antiestrogens and progestational drugs in carcinoma of the breast in an advanced stage].
Palmeri R; Papalia E; Lazzara S; Belnome NA; Gorgone S; Calbo E; Melita P
Chir Ital; 1987 Apr; 39(2):185-92. PubMed ID: 2958166
[TBL] [Abstract][Full Text] [Related]
9. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.
Beex L; Pieters G; Smals A; Koenders A; Benraad T; Kloppenborg P
Cancer Treat Rep; 1981; 65(3-4):179-85. PubMed ID: 7237448
[TBL] [Abstract][Full Text] [Related]
11. The effects of sequential treatment with ethynyloestradiol and medroxyprogesterone acetate on oestrogen and progestogen receptors in breast cancer.
Ghilchik M; Shaikh NA; Beranek PA; Reed MJ; Braunsberg H
J Steroid Biochem; 1989; 34(1-6):403-5. PubMed ID: 2533948
[TBL] [Abstract][Full Text] [Related]
12. Sequential cyclic combined hormonal therapy for metastatic breast cancer.
Hortobagyi GN; Hug V; Buzdar AU; Kau SW; Holmes FA; Fritsche HA
Cancer; 1989 Sep; 64(5):1002-6. PubMed ID: 2527085
[TBL] [Abstract][Full Text] [Related]
13. Cyclical sequential hormonochemotherapy in advanced breast cancer.
Ghilchik MW; Shaikh NA; Beranek PA; Reed MJ
Br Med J (Clin Res Ed); 1987 Nov; 295(6607):1172. PubMed ID: 3120930
[No Abstract] [Full Text] [Related]
14. [Results of a pilot study with high-dose medroxyprogesterone acetate in the treatment of metastasizing breast carcinoma].
Castiglione M; Cavalli F
Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1073-6. PubMed ID: 7423153
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
Chevallier B; Roche H; Olivier JP; Chollet P; Hurteloup P
Am J Clin Oncol; 1993 Jun; 16(3):223-8. PubMed ID: 8338056
[TBL] [Abstract][Full Text] [Related]
16. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
[TBL] [Abstract][Full Text] [Related]
17. [Preliminary results of treatment of hormone-dependent metastatic carcinoma of the breast with the bromocriptin-medroxyprogesterone acetate combination].
Mussa A; Dogliotti L; Di Carlo F
Minerva Med; 1977 Jun; 68(32):2233-44. PubMed ID: 577604
[TBL] [Abstract][Full Text] [Related]
18. [High-dosage oral gestagen therapy as a failure-regime in metastatic breast cancer].
Jonat W; Knapp W; Schumann B; Trapp H; Vanhecke C; Maass H
Dtsch Med Wochenschr; 1984 Jan; 109(2):46-9. PubMed ID: 6692762
[TBL] [Abstract][Full Text] [Related]
19. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
20. New regimen of combination hormone therapy (ME-TA-MAP) in the treatment of advanced breast cancer. A pilot study.
Pannuti F; Martoni A; Fruet ; Marraro D; Strocchi E
Panminerva Med; 1981; 23(3):157-60. PubMed ID: 7335366
[No Abstract] [Full Text] [Related]
[Next] [New Search]
